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Abstract
A comparative analysis of genome-scale transcriptomic data of two types of skin cancers, melanoma and basal cell
carcinoma in comparison with other cancer types, was conducted with the aim of identifying key regulatory factors that
either cause or contribute to the aggressiveness of melanoma, while basal cell carcinoma generally remains a mild disease.
Multiple cancer-related pathways such as cell proliferation, apoptosis, angiogenesis, cell invasion and metastasis, are
considered, but our focus is on energy metabolism, cell invasion and metastasis pathways. Our findings include the
following. (a) Both types of skin cancers use both glycolysis and increased oxidative phosphorylation (electron transfer
chain) for their energy supply. (b) Advanced melanoma shows substantial up-regulation of key genes involved in fatty acid
metabolism (b-oxidation) and oxidative phosphorylation, with aerobic metabolism being far more efficient than anaerobic
glycolysis, providing a source of the energetics necessary to support the rapid growth of this cancer. (c) While advanced
melanoma is similar to pancreatic cancer in terms of the activity level of genes involved in promoting cell invasion and
metastasis, the main metastatic form of basal cell carcinoma is substantially reduced in this activity, partially explaining why
this cancer type has been considered as far less aggressive. Our method of using comparative analyses of transcriptomic
data of multiple cancer types focused on specific pathways provides a novel and highly effective approach to cancer studies
in general.
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Introduction
The rapidly increasing pool [1,2] of large-scale transcriptomic
data for various cancer types has provided unprecedented
opportunities for computational cancer biologists to study
common characteristics across multiple cancer types as well as
distinct properties of individual cancer types, which could provide
novel insights about different cancer phenotypes at the molecular
level. Here we present a comparative analysis of transcriptomic
data collected on cancer and control tissue samples of two skin
cancer types, melanoma and basal cell carcinoma, which have
very distinct characteristics.
Skin cancer is one of the most common cancer types in the
USA. Currently over 3.5 million cases of skin cancers are
diagnosed and reported annually [3]. It has been estimated that
three out of ten Caucasians will develop skin cancer during their
lifetime [4]. The most common skin cancer is basal cell carcinoma
(BCC), which develops in the basal cell layer of the skin, and
primarily occurs in fair-skinned individuals. Sunlight is known to
be a major factor for causing the disease. BCC is rarely deadly
since it generally does not metastasize [5]. In contrast, melanoma
is a rare type of skin cancer but is among the deadliest forms of
cancers [6]. The tumor is derived from melanocytes, cells that
produce the dark pigment. While melanoma is not limited to skin,
it generally starts from the skin. A number of genes or their
mutations have been found to be associated with the development
of melanoma such as MC1R [7], CDK4 [8] and CDKN2A [9].
The early stage of the disease is referred to as the radial growth phase
when the tumor grows mostly horizontally. The behavior of the
tumor drastically changes as soon as it starts to grow vertically, i.e.,
entering the vertical growth phase. It generally starts invading
neighboring tissues when its thickness goes beyond 1 mm [10].
While some information is known about the potential causes of
the two skin cancer types, such as excessive exposure to sunlight
and development of the basal-cell nevus syndrome being the main
causes of basal cell carcinoma and a few rare mutations in the
aforementioned genes being the main reason for the development
of melanoma, a detailed understanding about why the two skin
cancer types behave so differently remains to be very limited.
Through comparative analyses of genome-scale transcriptomic
data on the two cancer types, we have gained a number of new
insights which could shed new lights on our efforts to understand
the detailed mechanisms of these two rather different skin cancer
types. To put our analysis in a larger context, seven other cancer
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30750types have also been included, which range from relatively slow
growing cancer to the fastest growing cancers, i.e, prostate,
breast, kidney, colon, stomach, lung and pancreatic. By using
transcriptomic data collected on cancer versus control tissues and
comparing expression changes of the genes involved in different
pathways associated with energy metabolism, we found that: (i)
multiple genes involved in oxidative phosphorylation are up-
regulated in both melanoma and BCC, which is unique to only
skin cancers among the nine types of cancer we examined and is
inconsistent with Warburg’s thesis [11]; (ii) interestingly, the key
enzyme in ATP generation in the oxidative phosphorylation
pathway is up-regulated only in advanced melanoma but not in
any form of BCC; (iii) the level and scale of up-regulated genes
involved in cell invasion and metastasis in advanced melanoma
are comparable to those of pancreatic cancer, while the
corresponding values in BCC are essentially at the lower end
among all the nine cancer types we examined. We believe that
our comparative transcriptomic data analyses of multiple cancer
types focused on specific cancer related pathways provide a novel
and highly effective approach to cancer studies, which could lead
to substantial new insights about cancer formation (when the
relevant data are available) and progression.
Results
Our analysis was done on two gene-expression datasets. One set
consisted of 52 tissue samples for the study of melanoma. Of the 52
tissue samples, 18 were common nevi (moles) (CMN), 11 were
dysplastic nevi (pre-cancerous) (DN), 8 in the radial growth phase
(RGP) (early stage) and 15 in the vertical growth phase (VGP)
(advanced stage) [12]. For this particular dataset, the common nevi
tissues were used as the control set since the original study did not
include normal skin tissues [12]. The second set consisted of 31
tissues for the study of BCC. Of the 31 tissue samples, 8 were in
the superficial form (early stage), 7 in the morphea form
(intermediate stage) and 8 in the nodular form (advanced stage),
along with 8 normal skin epithelial tissues as the control [13].
1. Differentially expressed genes in the two skin cancer
types
In this study, a gene is considered differentially expressed at a
specific stage of a cancer if the distribution of its expression levels
among cancer tissues at that stage is deemed to be statistically
different from the distribution of its expression levels among the
control tissues (see Material and Methods). For BCC, 158, 406 and
494 genes were found to be differentially expressed in the
superficial, morphea and nodular forms, respectively, compared
to the controls, which is consistent with our previous observation
that the number of differentially expressed genes increases as a
cancer advances [14,15]. Using the same cutoff, 123, 326 and
1,647 genes were deemed to be differentially expressed in DN,
RGP and VGP melanoma. In our previous study, we found that
there is a strong correlation between the number of differentially
expressed genes and the five-year survival rate associated with a
particular cancer [14]. Thus, the high number of differentially
expressed genes in VGP melanoma is consistent with the clinical
statistics regarding the mortality rate of this cancer. There is a
possibility that this number could be potentially under-estimated
since the controls (moles) for the melanoma analysis are not
normal skin tissues and moles are probably the first step moving
towards melanoma. The detailed lists of differentially expressed
genes are given in Table S1. Overall it was found that the numbers
of differentially expressed genes in the two cancer types are
comparable in their early stages; and a substantial rise in the
number of differentially expressed genes in the advanced stage,
VGP, of melanoma was observed.
A careful analysis of the pathways in the KEGG database that
are enriched by the differentially expressed genes among the
cancer tissues of BCC and melanoma was conducted with the
DAVID program (see Material and Methods). For BCC, no
pathways were found to be clearly enriched in the early stage,
while 19 and 18 pathways were enriched in the intermediate and
advanced stages, respectively. For melanoma, 1, 8 and 61
pathways were enriched in the DN, RGP and VGP forms,
respectively. The names of these enriched pathways are given in
Table S2.
It was noted that 11 enriched pathways are specific to VGP
melanoma, the deadliest form among all the skin cancer types,
including pathways associated with amino sugar and nucleotide
sugar metabolism, linoleic acid metabolism and the citratric acid
cycle (TCA cycle). In addition, some pathways are significantly
enriched in only melanoma among the two skin cancer types
considered, such as fatty acid metabolism, cell cycle, apoptosis and
the ErbB signaling pathway. For BCC, it was noted that its
advanced stage cancer has three pathways uniquely enriched
among all the cancer types under consideration, including the
spliceosome, GnRH signaling and long-term potentiation path-
ways.
We have also checked if some of the annotated proto-oncogene
and tumor-suppressor genes (http://www.uniprot.org/keywords/)
show differential expressions in BCC and melanoma. Overall it
was found that 2, 5 and 4 oncogenes are over-expressed in early,
intermediate and advanced stage of BCC samples, respectively,
and 0, 1 and 0 tumor suppressor genes are respectively under-
expressed in the three stages. Similarly, for melanoma, 9, 1 and 32
oncogenes are over-expressed in precancerous, early stage and
advanced melanoma, respectively, and 0, 4 and 4 tumor
suppressor genes are respectively under-expressed in the three
stages.
Some of these up-regulated oncogenes have been reported as
key regulatory genes for some of the skin cancer types. Among the
up-regulated oncogenes in melanoma, ABL2, NRAS, PDGFC and
FGF1 have been reported to be melanoma-associated oncogenes
[16]. Thus, RAB6B, REL and WHSC1L1, as identified by our
analysis, may represent additional oncogenes for melanoma. For
BCC, HRAS, RRAS and RUNX1 have been reported as BCC-
associated oncogenes [17]. Hence, ECT2, PLAG1, RAB6C and
SSPN, identified by our analysis, may represent additional
oncogenes for BCC. It is interesting that nine oncogenes exhibit
up-regulation in the pre-cancer stage of melanoma, which may be
the initial switch of the tumorgenesis leading to melanoma.
Moreover, the large increase in the number of up-regulated
oncogenes in VGP melanoma may suggest the aggressiveness of
the cancer. A detailed list of all the identified oncogenes and
tumor-suppressor genes is given in Figure S1.
2. Differentially expressed genes involved in energy
metabolism
We have examined expression fold-changes of genes involved in
four energy metabolic pathways: glycolysis, fatty acid metabolism,
the TCA cycle and oxidative phosphorylation (also called the
electron transfer chain) in the two skin cancer types and compared
them with the other seven non-skin cancer types. Figure 1 shows
expression level changes of genes involved in the four energy
pathways of the two skin cancer types and the other seven cancer
types. By examining the figure, the following observations can be
made.
Comparative Study Reveals New Insights of Cancer
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30750Comparative Study Reveals New Insights of Cancer
PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e307501. Substantial increases in expression levels of multiple genes
involved in glycolysis are observed in both the advanced forms
of the two skin cancer types and five of the seven reference
cancer types, namely kidney, colon, stomach, lung and
pancreatic, consistent with Warburg’s thesis [18].
2. Two enzyme-encoding genes involved in fatty acid metabolism
show substantial up-regulation in both BCC and melanoma, in
contrast to the seven non-skin cancer, indicating a unique way
that skin cancer obtains energy not only from glucose
metabolism like other cancers but also from fatty acid
metabolism, which is a more efficient energy generation
pathway.
3. Moderately increased expression levels of genes involved in the
TCA cycle are also observed in advanced melanoma, along
with breast, colon, stomach and lung cancers.
4. Most interesting is the finding that multiple genes involved in
oxidative phosphorylation are up-regulated in the advanced
form of both skin cancer types, which strongly suggests that
both skin cancer types obtain much of their energy through
oxidative phosphorylation, which produces an order of
magnitude more ATPs than each of the other three energy
pathways (per glucose). This is very surprising as this indicates
the two skin cancer types, even in their advanced forms, are not
under hypoxic condition, and hence do not show the Warburg
effect.
5. ATP synthase is up-regulated only in advanced melanoma, in
addition to the protein complex responsible for electron
transfer but not in any form of BCC, indicating that ATP
synthesis is faster in advanced melanoma than BCC.
Further analysis of the differentially expressed genes in
advanced melanoma suggests that the increased levels of
acetyl-CoA, NADH and FADH2 derived from fatty acid
oxidation can enter mitochondria and undergo oxidative
phosphorylation. This process would be highly advantageous
for a tumor as b-oxidation of fatty acids yields a larger number of
acetyl-CoA molecules compared to glycolysis, and thus it has a
larger number of substrates for the TCA cycle and subsequent
oxidative phosphorylation. In order to utilize the increased
number of acetyl-CoAs, the cells may need to have an increased
rate of oxidative phosphorylation. Acetyl-CoA is an allosteric
inhibitor of the PDH enzymes. As we observed, PDHA2 is
substantially down-regulated in VGP melanoma, which can be
attributed to the increased level of acetyl-CoA. As the PDHA2
activity decreases, pyruvate will naturally be diverted to lactic
acid formation, which is shown by the up-regulation of LDHA
and lactate transporters (MCT proteins SLC16As 3&6). Figure 2
gives an energy model for advanced melanoma based on the
results of our data analysis.
3. Differentially expressed genes involved in tumor
invasion and metastasis
We have studied expression changes of genes involved in the
metastatic process, with the goal of identifying possible reasons
why the two skin cancer types have substantial differences in their
ability to metastasize. For this, focus was placed on the pro-
metastasis gene families, namely the positive regulation of the
epithelial-mesenchymal transition (EMT), the negative regulation
of cell adhesion, the chemokine and MMP families, both of which
promote degradation of extracellular matrices. Figure 3 shows the
observed expression changes of genes involved in these processes
of the two skin cancer types, along with the other seven cancer
types. We have made the following observations from the data in
Figure 3.
1. The VGP melanoma has the greatest number of up-regulated
genes involved in the pro-metastasis gene family, having even
more such genes than pancreatic cancer; While simply
counting the number of up-regulated genes may be a rather
crude way to assess the ability of a cancer to metastasize,
Figure 4 shows that there is a strong (negative) correlation
between this number and the five-year survival rate of a
cancer.
2. VGP melanoma is the only skin cancer type with up-regulated
genes involved in positive regulation of the epithelial-
mesenchymal transition, which is considered to be the crucial
developmental and regulatory program for cell invasion and
metastasis [19,20]; in addition, the significant up-regulation of
genes involved in degrading the cell-cell adhesion molecules
and the increased negative regulation of the cell adhesion, the
matrix metalloproteinases and chemokines all suggest that
VGP is highly metastatic [21].
3. The lymphatic spread represents a major way for metastasis.
We noted that the number of differentially expressed genes in
lymphocyte proliferation is much higher in VGP melanoma
compared to all the other skin cancer subtypes under
consideration (see Figure S2).
4. It has been reported that a chaotic circadian rhythm may
lead to faster tumor growth [22]. From the above figure, we
noted that key genes of the circadian rhythm pathway are
differentially expressed in VGP melanoma but only to a very
limited extent in other skin cancer subtypes under
consideration. CRY2, the most important gene controlling
cell circadian rhythm [23], shows down-regulation only in
VGP melanoma among all the cancer types under
consideration. Items (2)–(4) above suggest that VGP
melanoma has the greatest activities for cell-invasion and
metastasis.
5. In contrast, only a few genes of BCC are up-regulated in the
aforementioned processes. Among the two different BCC
subtypes, it is the morphea form not the nodular form, that has
the most up-regulated genes, which is consistent with previous
reports that this form represents the BCC form with the
greatest number of metastasis cases [24]. We observed that in
the morphea BCC, a number of genes encoding the collagens
and proteins involved in anti-metastasis are highly up-
regulated, suggesting that the cancer is under the control of
the immune system in inhibiting its invasion and metastasis
throughout its development.
Overall our analysis suggests that VGP melanoma has the
highest potential and unique ability to metastasize among the
cancer types studied herein, while the BCC’s ability to metastasize
is the weakest among the nine types of cancers under
consideration.
Figure 1. Expression level changes of genes involved in the four types of energy metabolism for two skin cancer types and seven
non-skin cancer types. Each row represents expression changes of a gene across all the cancer types under study. Rate limiting enzymes in each
pathway are indicated using *. Each column represents one cancer type. The fold change of gene expression is color-coded with red, white and green
for up-, no and down-regulation.
doi:10.1371/journal.pone.0030750.g001
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4a. Differentially expressed genes involved in cell
proliferation. Self-sufficiency in growth signals is a major
acquired capability of any cancer. Our analysis of differentially
expressed genes involved in positive regulation of cell proliferation
indicates that VGP melanoma has substantially more genes up-
regulated in this category than all the other skin cancer forms.
Specifically, we noted that the number of such up-regulated genes
is comparable to that of the pancreatic cancer with the detailed
data given in Figure S3. Particularly worth noting is that VGP
melanoma is the only cancer type among the nine cancer types
showing substantial up-regulation of the genes of the Jak-STAT
signaling pathway, which is a crucial pathway that promotes cell
growth.
4b. Differentially expressed genes involved in
apoptosis. The morphea BCC, nodular BCC and VGP
melanoma all have numerous numbers of differentially expressed
genes involved in negative regulation of cell death as shown in
Figure S4. From this figure we can see an increasing trend in the
number of up-regulated genes as the cancer type becomes more
aggressive. Specifically it was noted that this number for VGP is
higher than all the other cancer types under consideration except
for the pancreatic cancer.
4c. Differentially expressed genes involved in
angiogenesis. None of the skin cancer types show increased
activities of angiogenesis, unlike the advanced form of the other
cancers as shown in Figure 5. This observation is consistent with
our earlier finding that skin cancers are generally not under
hypoxic stress and hence probably have no pressure to activate the
angiogenesis pathway.
5. Signature genes for the two skin cancer types
We have predicted signature genes and gene groups for
melanoma and BCC, respectively, where a signature (or marker)
gene or gene group refers to genes whose expression pattern is
unique to a specific cancer type. We then tested the performance
of the identified signature genes for the two cancer types,
respectively, on two datasets, independent of the training datasets
used, i.e., GSE3189 for melanoma and GSE12542 for BCC. For
melanoma, the top five 1-gene signatures, OAS3 (82.9% on training
and 71.4% on testing set), RALBP1 (82.9% on training and 71.4%
on testing set), GLA (80.4% on training and 71.4% on testing set),
LLGL1 (80.4% on training and 71.4% on testing set) and
SERPINA6 (80.4% on training and 71.4% on testing set), all have
better than 80% classification accuracy between melanoma cases
and control cases in the test set. Among the top markers, OAS3 and
SERPINA6 are predicted to be blood secretory by our prediction
program[25],hencesuggestingthepotentialfeasibility inidentifying
diagnostic markers for melanoma through blood tests. Similarly,
four 1-gene signatures with classification accuracy better that 71%
are predicted to be urine excretory, CCL18 (73.2% on training and
71.4% on testing set), HEXB (73.2% on training and 71.4% on
testing set), IFI30 (73.2% on training and 71.4% on testing set) and
STC1 (73.2% on training and 71.4% on testing), by using our
prediction program [26], suggesting the potential feasibility in
identifying diagnostic markers for melanoma through urine tests.
Among the top 2-gene signatures, three pairs reach classification
accuracy better than 85% on both the training and the testing
datasets. Three pairs, with training classification accuracies better
than 90% and testing classification accuracy better than 70%, are
predicted to be blood secretory and only 1 pair CTSK_RNASE6
(87.8% on training and 73.0% on testing sets), with training
Figure 2. A model for energy metabolism for VGP melanoma.
doi:10.1371/journal.pone.0030750.g002
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doi:10.1371/journal.pone.0030750.g003
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statistical significance cutoff (see Material and Methods). The x-axis is the five-year survival rate ranging from 0 to 100% (data used from
www.cancer.org), and the y-axis is the number of differentially expressed genes for each cancer type.
doi:10.1371/journal.pone.0030750.g004
Figure 5. Expression changes of genes involved in the pro-angiogenesis of the two skin cancer types and other seven non-skin
cancer types.
doi:10.1371/journal.pone.0030750.g005
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accuracy better than 70%, are predicted to be urine excretory.
For BCC, the top two 1-gene markers, CS (90.3% on training
and 87% on testing set) and TACSTD1 (87.1% on training and
87% on testing dataset), both have at least 87% classification
accuracy on both the training and testing datasets. Among the top
markers, EGR1 (87.1% on training and 81.3% on testing set) is
predicted to be blood secretory. Similarly, RAB3D (80.6% on
training and 80% on testing dataset) is predicted to be urine
excretory, with a classification accuracy better that 80% in both
sets, providing potential diagnostic markers for melanoma through
urine tests. The top two 2-gene signatures all have classification
accuracies better than 90% on both the training and testing sets.
Also, four pair signatures, with classification accuracy better than
80% on both the training and testing sets, are predicted to encode
blood secretory proteins. The detailed list of all these marker genes
is given in Table S3.
Materials and Methods
1. Microarray gene expression data for nine cancer types
Microarray gene expression data for both skin cancer types
were downloaded from the GEO database of NCBI [27]. The
melanoma data is the dataset GSE12391 and the BCC data is the
dataset GSE6520. The gene-expression data for the seven cancer
types used in this study: breast, colon, kidney, lung, pancreatic,
prostate and stomach, are also downloaded from the GEO
database of NCBI. For each dataset used for each cancer type, we
have made sure that the dataset was generated using the same
platform by the same research group. For each of the classification
problem solved in this study, we have used a training dataset and a
separate testing set for each cancer type. The details of the data are
given in Table S4.
Considering that different microarray datasets used in this study
cover different gene sets, we have considered the genes that belong
to all microarray datasets used in this study for all the comparative
analyses throughout this paper, which consists of 4,401 genes. The
detailed list of these genes is given in Table S5. When mapping
genes across different datasets, we rely on the NCBI gene IDs of
the genes, i.e., two genes in different datasets are considered as the
same genes if their IDs are identical.
The cancer gene list is downloaded from the Cancer Gene
Census website, which contains 457 confirmed cancer genes
(http://www.sanger.ac.uk/genetics/CGP/Census/).
2. Identification of differentially expressed genes
For each dataset used in this study, we have used the
normalized expression data from the original study. We fully
understand that gene-expression data across different datasets
may not necessarily directly comparable; so we have compared
the fold-changes between the diseased and the control tissues for
each cancer type with fold-changes of expression data of another
cancer type. Figure S5 shows that the global fold-changes
between two cancer types are generally comparable across the
nine cancer types under consideration. It should be noted that
when calculating the fold-change of an individual gene for a
specific cancer type, we did not use the information of paired
diseased-control tissues, instead we estimated the fold change
based on the distributions of gene-expressions of the gene across
all the cancer tissues versus control tissues, for each cancer type.
We did so because some of the datasets have paired information
wile other datasets do not.
For each dataset, the Mann-Whitney test was applied to identify
genes that are differentially expressed in cancer versus control
samples as follows: Given the null hypothesis H0 that a gene is not
differentially expressed between the cancer versus the control groups,
rejection of this hypothesis means that the gene is differentially
expressed in cancer. We consider a gene as up-regulated if the
statistical significance, p-value, is less than 0.01 and its fold-increase
is at least 1.5. A down-regulated gene is defined similarly.
For the non-skin cancer data, we only consider those genes with
consistent up/down-regulation in both the training and the testing
data sets as differentially expressed genes.
3. Pathway enrichment analysis of differentially
expressed genes
Functional analysis and pathway enrichment analysis were
conducted using DAVID [28], where the pathway information
is based on the annotation from KEGG (http://www.genome.ad.
jp/kegg/). A p-value,0.05 was used as the threshold to
determine if a pathway is enriched or not by the identified
differentially expressed genes. Note that the observations made
throughout this paper are generally stable with respect to the p-
value cutoff. Also note all the pathway enrichment analysis is
based on the 4,401 genes that are shared by all the datasets used
in this study.
4. Prediction of signature genes
To derive signature genes or gene groups, we conducted an
exhaustive search for all the k-gene (k=1, 2) combinations among
the differentially expressed genes, using a linear SVM-based
classifier. We have used 5-fold cross validation to validate each
identified signature. We refer the reader to [29] for the detailed
procedure used.
Discussion
Our gene-expression data analysis revealed that both skin
cancer types utilize oxidative phosphorylation as the key energy
metabolism in addition to glycolysis. All evidence revealed by our
study strongly indicates that the two skin cancer types are not
under hypoxic stress, hence explaining why the two cancer types
do not show the Warburg effect. The high energy metabolism in
melanoma, powered by the substantially more efficient energy
pathway, the up-regulated oxidative phosphorylation compared to
the alternatives, along with its high ability to metastasize,
explained why the cancer is so aggressive. In contrast, BCC,
while using energy from oxidative phosphorylation, seems to have
an obvious block from the immune system, which appears to
prevent cell invasion and metastasis, hence making the cancer one
of the least deadly cancers.
The new insights derived in this study are global in nature and
lack of detailed mechanism information due to the low-resolution
nature of the non-paired datasets used in this study. We anticipate
that higher-resolution insights could be derived using the same
computational approach but on paired cancer-control datasets.
We believe that our study provides a new and highly effective
way to gain new insights and understanding about certain unique
characteristics of different cancers in their formation and
progression through mining large-scale gene-expression data
across multiple cancer types, but focused on key relevant cancer
pathways.
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